tiprankstipranks
Trending News
More News >

BioCryst Appoints New CFO to Drive Growth

Story Highlights
BioCryst Appoints New CFO to Drive Growth

Don’t Miss TipRanks’ Half-Year Sale

BioCryst ( (BCRX) ) has shared an update.

On July 7, 2025, BioCryst Pharmaceuticals announced the appointment of Babar Ghias as Chief Financial Officer and Head of Corporate Development. Mr. Ghias brings extensive experience from his previous roles at AvenCell Therapeutics and Paragon Biosciences, where he was instrumental in launching biotechnology companies and raising significant capital. His appointment is expected to bolster BioCryst’s leadership team as the company aims to accelerate growth and enhance value creation. This strategic move is seen as pivotal for BioCryst’s operational excellence and financial discipline, supporting its ambitious growth plans.

The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst faces significant financial challenges with persistent net losses and negative equity, heavily influencing its stock score. Despite positive earnings call outcomes and strategic corporate actions, the technical indicators suggest bearish momentum, and valuation metrics highlight high risk.

To see Spark’s full report on BCRX stock, click here.

More about BioCryst

BioCryst Pharmaceuticals is a global biotechnology company dedicated to improving the lives of individuals with hereditary angioedema and other rare diseases. The company specializes in structure-guided drug design to develop innovative oral small-molecule and protein therapeutics aimed at treating challenging diseases. BioCryst has successfully commercialized ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Average Trading Volume: 4,732,000

Technical Sentiment Signal: Buy

Current Market Cap: $1.87B

See more insights into BCRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1